In the debut episode of The Comment Period, Gardner Law attorneys examine how shifts in FDA leadership, policy, and enforcement are affecting FDA-regulated companies. The discussion covers direct-to-consumer advertising, AI at FDA, Whoop, peptides, digital health, and the practical challenges companies face when regulatory expectations are changing faster than the formal rules.